Document is current

Article History

Accepted: 20 November 2024

First Online: 21 December 2024

Declarations

:

: This study was funded by Genmab A/S and AbbVie.

: T.L., M.v.d.L., K.S., M.P., M.S., H.F., T.A., M.G., and S.X. are employees of Genmab. T.A. owns stock in Genmab. L.G. is an employee of QuantPharm LLC and is a paid consultant of Genmab. A.P. is an employee and stockholder of AbbVie.

: Deidentified individual participant data will not be available upon request for further analyses by external independent researchers. Aggregated clinical trial data from the trials are provided via publicly accessible study registries/databases as required by law. For more information, please contact clinicaltrials@genmab.com.

: Both EPCORE NHL-1 and EPCORE NHL-3 protocols were approved by an institutional ethics committee before the start of the trials. The trials were conducted in compliance with the International Council for Harmonisation Good Clinical Practice E6(R2) guidelines, local guidelines (Japan Good Clinical Practice for EPCORE NHL-3), principles of the Declaration of Helsinki, and relevant regulatory requirements.

: All patients reviewed and signed informed consent forms before enrollment.

: Because of the nature of this study, consent to publish was waived.

: Conceptualization: T.L., A.P., M.G., and S.X. Methodology: T.L., L.G., and M.v.d.L. Formal analysis and investigation: T.L., L.G., M.v.d.L, M.S., and H.F. Writing, original draft preparation: T.L. and S.X. Funding acquisition: T.L. and M.G. Resources: K.S. and M.P. Supervision: T.L., M.G., and S.X. All authors participated in the critical review and revision of this manuscript and provided approval of the manuscript for submission.

: Not applicable.